Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1831 to 1845 of 8975 results

  1. Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]

    Topic prioritisation

  2. Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]

    Topic prioritisation

  3. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]

    Topic prioritisation

  4. Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]

    Topic prioritisation

  5. AHEAD implants for external ear prosthesis

    Topic prioritisation

  6. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

  7. Wireless breast lesion localization using Savi Scout seed

    Topic prioritisation

  8. Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)

    Topic prioritisation

  9. In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death

    In development Reference number: GID-IPG10405 Expected publication date:  19 November 2026

  10. Middle meningeal artery embolisation for chronic subdural haematomas

    In development Reference number: GID-IPG10440 Expected publication date:  19 November 2026

  11. Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 14 April 2026.

  12. Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

    In development Reference number: GID-TA11963 Expected publication date: TBC

  13. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

    In development Reference number: GID-TA11373 Expected publication date: TBC

  14. Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [ID6694]

    Awaiting development Reference number: GID-TA11933 Expected publication date: TBC